購(gòu)物車 
-
奈韋拉平
- names：
Nevirapine
- CAS號(hào)：
129618-40-2
MDL Number： MFCD00866928 - MF(分子式)： C15H14N4O MW(分子量)： 266.3
- EINECS:603-345-0 Reaxys Number:No data available
- Pubchem ID:4463 Brand:BIOFOUNT
奈韋拉平Nevirapine(129618-40-2,BIRG587)是用于治療和預(yù)防HIV / AIDS的HIV-1逆轉(zhuǎn)錄酶非核苷抑制劑，Ki：270μM（HIV-1逆轉(zhuǎn)錄酶）。奈韋拉平也是苯二氮雜非核苷逆轉(zhuǎn)錄酶抑制劑，與其他抗逆轉(zhuǎn)錄病毒藥物合用時(shí)，奈韋拉平可降低HIV病毒載量并增加CD4計(jì)數(shù)，從而延緩或防止免疫系統(tǒng)受損，并降低患上艾滋病的風(fēng)險(xiǎn)。
| 貨品編碼 | 規(guī)格 | 純度 | 價(jià)格 (￥) | 現(xiàn)價(jià)(￥) | 特價(jià)(￥) | 庫(kù)存描述 | 數(shù)量 | 總計(jì) (￥) |
|---|---|---|---|---|---|---|---|---|
| YZM000630-50mg | 50mg | 99.81% | ￥ 1113.00 | ￥ 1113.00 | 2-3天 | ￥ 0.00 | ||
| YZM000630-10mg | 10mg | 99.81% | ￥ 507.00 | ￥ 507.00 | 2-3天 | ￥ 0.00 |
- 大包裝詢價(jià) 提供各種包裝，敬請(qǐng)垂詢
- 收藏商品 商品點(diǎn)評(píng) 加入購(gòu)物車 立即購(gòu)買
| 中文別名 | 奈韋拉平(129618-40-2,BIRG587),奈夫拉平,奈偉拉平,奈韋拉平,萘維拉平,11-環(huán)丙基-5,11-二羥基-4-甲基-6H-二吡啶并[3,2-b:2',3'-e][1,4]二氮雜唑-6-酮; |
| 英文別名 | Nevirapine(129618-40-2,BIRG587);BI RG 587;BI-RG-587;BIRG587;Hemihydrate, Nevirapine;Nevirapine Hemihydrate;Viramune; |
| CAS號(hào) | 129618-40-2 |
| Inchi | InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20) |
| InchiKey | NQDJXKOVJZTUJA-UHFFFAOYSA-N |
| 分子式 Formula | C15H14N4O |
| 分子量 Molecular Weight | 266.3 |
| 溶解度Solubility | 生物體外In Vitro:DMSO溶解度14.29 mg/mL(53.66 mM;Need ultrasonic) |
| 性狀 | 吡啶和水結(jié)晶白色至淺黃色固體,Power |
| 儲(chǔ)藏條件 Storage conditions | -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
奈韋拉平,Nevirapine(129618-40-2,BIRG587)實(shí)驗(yàn)注意事項(xiàng)：
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡，穿戴防護(hù)服和口罩，佩戴手套，避免與皮膚接觸。
2.實(shí)驗(yàn)過(guò)程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時(shí)實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對(duì)實(shí)驗(yàn)人員造成傷害
3.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類存儲(chǔ)，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tags:奈韋拉平試劑,奈韋拉平合成,奈韋拉平雜質(zhì),奈韋拉平中間體,奈韋拉平密度,奈韋拉平溶解度,奈韋拉平閃點(diǎn),奈韋拉平購(gòu)買,奈韋拉平MSDS,
| 產(chǎn)品說(shuō)明 | 奈韋拉平(129618-40-2,Nevirapine)是用于治療和預(yù)防HIV/AIDS的HIV-1逆轉(zhuǎn)錄酶非核苷的抑制劑,Nevirapine Ki值是270 μM. |
| Introduction | Nevirapine(129618-40-2,奈韋拉平) is a nonucleoside inhibitor of HIVreverse transcriptase used to treat and prevent HIV/AIDS; with aKiof 270 μM. |
| Application1 | |
| Application2 | |
| Application3 |
奈韋拉平(129618-40-2,Nevirapine)是苯二氮雜非核苷逆轉(zhuǎn)錄酶抑制劑。與其他抗逆轉(zhuǎn)錄病毒藥物合用時(shí)，奈韋拉平可降低HIV病毒載量并增加CD4計(jì)數(shù)，從而延緩或防止免疫系統(tǒng)受損，并降低患上艾滋病的風(fēng)險(xiǎn)。 奈韋拉平是一種非核苷類逆轉(zhuǎn)錄酶抑制劑，與其他藥物聯(lián)合用于治療人類免疫缺陷病毒（HIV）感染和獲得性免疫缺陷綜合癥（AIDS）。奈韋拉平與治療過(guò)程中血清氨基轉(zhuǎn)移酶升高的比率較高有關(guān)，并且是急性，臨床上明顯的肝損傷的公認(rèn)原因。 奈韋拉平是一種二吡啶并二氮雜卓，它是5,11-二氫-6H-二吡啶并[3,2-b：2'，3'-e] [1,4]二氮卓，在第4位被甲基，氧代和環(huán)丙基取代，6和11。具有抗HIV-1活性的非核苷類逆轉(zhuǎn)錄酶抑制劑，可與其他抗逆轉(zhuǎn)錄病毒藥物聯(lián)合用于治療HIV感染。它具有抗病毒藥和HIV-1逆轉(zhuǎn)錄酶抑制劑的作用。它是二吡啶并二氮雜pine和環(huán)丙烷的成員。
| 警示圖 | |
| 危險(xiǎn)性 | warning |
| 危險(xiǎn)性警示 | Not available |
| 安全聲明 | H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對(duì)身體有害 |
| 安全防護(hù) | P264處理后徹底清洗+P280戴防護(hù)手套/穿防護(hù)服/戴防護(hù)眼罩/戴防護(hù)面具+P305如果進(jìn)入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護(hù)理 |
| 備注 | 實(shí)驗(yàn)過(guò)程中防止吸入、食入，做好安全防護(hù) |
奈韋拉平Nevirapine(129618-40-2,BIRG587)危害標(biāo)識(shí)：
| 象形圖 | |
| 信號(hào) | Warning |
| GHS危險(xiǎn)說(shuō)明 | Aggregated GHS information provided by 23 companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
| H302 (17.39%): Harmful if swallowed [Warning Acute toxicity, oral] | |
| H412 (95.65%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard] | |
| Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. | |
| 防范說(shuō)明代碼 | P264, P270, P273, P301+P312, P330, and P501 |
| (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| Erickson DA, et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitornevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999 Dec;27(12):148 |
| Dong JJ, et al. In vitro evaluation of the therapeutic potential of nevirapine in treatment of human thyroid anaplastic carcinoma. Mol Cell Endocrinol. 2013 May 6;370(1-2):113-8. |
| Merluzzi VJ, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 1990 Dec 7;250(4986):1411-3. |
| Riska PS, et al. Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees. Drug Metab Dispos. 1999 Dec;27(12):14 |
| Onasanwo SA, et al. Evaluation of anti-ulcerogenic and ulcer-healing activities of nevirapine in rats. Afr J Med Med Sci. 2015 Sep;44(3):251-9. |
奈韋拉平Nevirapine(129618-40-2,BIRG587)參考文獻(xiàn)：
1. Is nevirapine atropisomeric? Experimental and computational evidence for rapid conformational inversion
Edmund W. D. Burke, Gareth A. Morris, Mark A. Vincent, Ian H. Hillier and Jonathan Clayden*. Org. Biomol. Chem., 2012, 10, 716–719
The question of atropisomerism in nevirapine was further highlighted early in 2011 in a paper, since withdrawn, claiming an optical rotation for a sample of nevirapine purportedly isolated from a natural source—something possible only if nevirapine can indeed exist as a pair of atropisomeric enantiomers. In response to this paper, and to the discussion it generated, we have quanti?ed, by spectroscopic and computational methods, the barrier to conformational inversion of nevirapine, and in this paperwe report our results.
2. Co-crystals of the antiretroviral nevirapine: crystal structures, thermal analysis and dissolution behaviour
Mino R. Caira,* Susan A. Bourne, Halima Samsodien. CrystEngComm, 2012, 14, 2541–2551
It has been established that nevirapine molecules associate as hydrogen-bonded (N–H…O]=C) centrosymmetric dimmers (Fig. 1(b)) in at least two polymorphs whose crystal structures are known. Furthermore, this supramolecular motif was found to occur almost exclusively in two series of nevirapine solvate structures that we reported recently. Co-crystallisation that might produce the species depicted in Fig. 1(c) and (d), containing analogous (but heteromeric) R22(8) hydrogen-bonded motifs, represents an obvious route to extending even further what we have observed to be nevirapine’s rich solid-state chemistry. While proposed heteromeric entities such as those shown in Fig. 1(c) and (d) appear to be structurally feasible, the observed robustness of the H-bonded nevirapine dimer (Fig. 1(b)) is a factor that could, however, thwart attempts at generating them. As indicated above, structural studies of nevirapine polymorphs and solvates had revealed the presence of the drug dimer in the vast majority of the crystals of these species, only the hemi- hydrate crystals containing a different motif. Speci?cally, the latter comprises two crystallographically independent nevirapine molecules linked to one another by a single N–H…O]=C bond only, water molecules serving as bridges between such pairs of drug molecules, with each water molecule engaging in three hydrogen bonds [as donor in OH…N(pyridine) and OH…O]C bonds, and as acceptor in a N–H…OH2 bond].
3. In search of a treatment for HIV – current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Chevonne Reynolds, Charles B. de Koning, Moira L. Bode*. Chem. Soc. Rev., 2012, 41, 4657–4670
NNRTIs on the other hand are small molecules that are chemically distinct from nucleosides and are not dependent on host cell metabolism to be converted into an active form. NNRTIs are a group of diverse hydrophobic molecules which inhibit the HIV-1 RT catalytic activity through interaction with an allosteric site of the enzyme. The binding of a non-competitive inhibitor in this allosteric site e?ects a change in conformation of the substrate-binding site which substantially reduces the rate of incorporation of nucleotides, thereby halting DNA synthesis. Five NNRTIs have been approved by the FDA for clinical use including nevirapine 5 (Viramune®), delavirdine 6 (Rescriptor®), efavirenz 7 (Sustiva®, Stocrin®), etravirine 8 (Intelence®) and, most recently in May 2011, rilpivirine 9 (Edurant®) (Fig. 4), and several more have entered into clinical trials and development. Nevirapine 5 and delavirdine 6 are considered ‘‘?rst-generation’’ NNRTIs that are sensitive to the development of drug resistance, even with single amino acid mutations in RT. Efavirenz 7,a “second-generation” NNRTI maintains antiviral activity against several common NNRTI mutants and is currently approved as ?rst-line regimen treatment in South Africa (replaced by nevirapine for pregnant women). The most recently approved NNRTIs, etravirine 8 and rilpivirine 9, are believed to require at least three amino acid mutations in the NNRTI region before clinically signi?cant resistance is observed.
4. Modelling the binding of HIV-reverse transcriptase and nevirapine: an assessment of quantum mechanical and force ?eld approaches and predictions of the e?ect of mutations on binding
Rajesh K. Raju, Neil A. Burton* and Ian H. Hillier*. Phys.Chem.Chem.Phys., 2010, 12, 7117–7125
There have been a number of quantum mechanical and molecular dynamics studies of the NNRTI binding site interactions of HIV-1 RT. Kuno et al. have calculated the interaction energies between nevirapine and key amino acid residues forming the NNRTI binding pocket at the MP2/6-31G(d,p) level, and have also employed a three layer ONIOM model, (MP2/6-31G(d,p):B3LYP/6-31G(d,p):PM3), to study the binding site interactions of nevirapine with HIV-1 RT. He et al. have reported the interaction energies of nevirapine with selected amino acid fragments for wild-type and K103N and Y181C mutants by employing the MFCC (Molecular Fractionation with Conjugate Caps) approach at the HF/6-31G and B3LYP/6-31G(d) level of theory. Srivab and Hannongbua have employed QM and ONIOM calculations to study the binding energies of efavirenz, to wild-type and K103/Y181C double mutant structures of HIV-1 RT. Kroeger et al. have employed the free energy perturbation (FEP) scheme within a Monte Carlo model to predict the e?ect of mutations on the binding of nevirapine and efavirenz to HIV-1 RT.
1. Is nevirapine atropisomeric? Experimental and computational evidence for rapid conformational inversion
Edmund W. D. Burke, Gareth A. Morris, Mark A. Vincent, Ian H. Hillier and Jonathan Clayden*. Org. Biomol. Chem., 2012, 10, 716–719
The question of atropisomerism in nevirapine was further highlighted early in 2011 in a paper, since withdrawn, claiming an optical rotation for a sample of nevirapine purportedly isolated from a natural source—something possible only if nevirapine can indeed exist as a pair of atropisomeric enantiomers. In response to this paper, and to the discussion it generated, we have quanti?ed, by spectroscopic and computational methods, the barrier to conformational inversion of nevirapine, and in this paperwe report our results.
2. Co-crystals of the antiretroviral nevirapine: crystal structures, thermal analysis and dissolution behaviour
Mino R. Caira,* Susan A. Bourne, Halima Samsodien. CrystEngComm, 2012, 14, 2541–2551
It has been established that nevirapine molecules associate as hydrogen-bonded (N–H…O]=C) centrosymmetric dimmers (Fig. 1(b)) in at least two polymorphs whose crystal structures are known. Furthermore, this supramolecular motif was found to occur almost exclusively in two series of nevirapine solvate structures that we reported recently. Co-crystallisation that might produce the species depicted in Fig. 1(c) and (d), containing analogous (but heteromeric) R22(8) hydrogen-bonded motifs, represents an obvious route to extending even further what we have observed to be nevirapine’s rich solid-state chemistry. While proposed heteromeric entities such as those shown in Fig. 1(c) and (d) appear to be structurally feasible, the observed robustness of the H-bonded nevirapine dimer (Fig. 1(b)) is a factor that could, however, thwart attempts at generating them. As indicated above, structural studies of nevirapine polymorphs and solvates had revealed the presence of the drug dimer in the vast majority of the crystals of these species, only the hemi- hydrate crystals containing a different motif. Speci?cally, the latter comprises two crystallographically independent nevirapine molecules linked to one another by a single N–H…O]=C bond only, water molecules serving as bridges between such pairs of drug molecules, with each water molecule engaging in three hydrogen bonds [as donor in OH…N(pyridine) and OH…O]C bonds, and as acceptor in a N–H…OH2 bond].
3. In search of a treatment for HIV – current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Chevonne Reynolds, Charles B. de Koning, Moira L. Bode*. Chem. Soc. Rev., 2012, 41, 4657–4670
NNRTIs on the other hand are small molecules that are chemically distinct from nucleosides and are not dependent on host cell metabolism to be converted into an active form. NNRTIs are a group of diverse hydrophobic molecules which inhibit the HIV-1 RT catalytic activity through interaction with an allosteric site of the enzyme. The binding of a non-competitive inhibitor in this allosteric site e?ects a change in conformation of the substrate-binding site which substantially reduces the rate of incorporation of nucleotides, thereby halting DNA synthesis. Five NNRTIs have been approved by the FDA for clinical use including nevirapine 5 (Viramune®), delavirdine 6 (Rescriptor®), efavirenz 7 (Sustiva®, Stocrin®), etravirine 8 (Intelence®) and, most recently in May 2011, rilpivirine 9 (Edurant®) (Fig. 4), and several more have entered into clinical trials and development. Nevirapine 5 and delavirdine 6 are considered ‘‘?rst-generation’’ NNRTIs that are sensitive to the development of drug resistance, even with single amino acid mutations in RT. Efavirenz 7,a “second-generation” NNRTI maintains antiviral activity against several common NNRTI mutants and is currently approved as ?rst-line regimen treatment in South Africa (replaced by nevirapine for pregnant women). The most recently approved NNRTIs, etravirine 8 and rilpivirine 9, are believed to require at least three amino acid mutations in the NNRTI region before clinically signi?cant resistance is observed.
4. Modelling the binding of HIV-reverse transcriptase and nevirapine: an assessment of quantum mechanical and force ?eld approaches and predictions of the e?ect of mutations on binding
Rajesh K. Raju, Neil A. Burton* and Ian H. Hillier*. Phys.Chem.Chem.Phys., 2010, 12, 7117–7125
There have been a number of quantum mechanical and molecular dynamics studies of the NNRTI binding site interactions of HIV-1 RT. Kuno et al. have calculated the interaction energies between nevirapine and key amino acid residues forming the NNRTI binding pocket at the MP2/6-31G(d,p) level, and have also employed a three layer ONIOM model, (MP2/6-31G(d,p):B3LYP/6-31G(d,p):PM3), to study the binding site interactions of nevirapine with HIV-1 RT. He et al. have reported the interaction energies of nevirapine with selected amino acid fragments for wild-type and K103N and Y181C mutants by employing the MFCC (Molecular Fractionation with Conjugate Caps) approach at the HF/6-31G and B3LYP/6-31G(d) level of theory. Srivab and Hannongbua have employed QM and ONIOM calculations to study the binding energies of efavirenz, to wild-type and K103/Y181C double mutant structures of HIV-1 RT. Kroeger et al. have employed the free energy perturbation (FEP) scheme within a Monte Carlo model to predict the e?ect of mutations on the binding of nevirapine and efavirenz to HIV-1 RT.
對(duì)不起，暫無(wú)產(chǎn)品評(píng)價(jià)！
MSDS
SDS 1.0 中文
展開(kāi)
SDS 1.0 英文
展開(kāi)
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)
細(xì)胞爬片免疫組化染色，是通過(guò)細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi)，細(xì)胞在玻片上生長(zhǎng)，主要用于組織學(xué)，免疫組織化學(xué)...
2020/7/20 22:04:33
提取病毒RNA的實(shí)驗(yàn)方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
脂.png)
chelex 100樹(shù)脂國(guó)產(chǎn)替代之路-BIOFOUNT范德生物
Chelex 100螯合離子交換樹(shù)脂對(duì)銅、鐵和其他重金屬?的偏好顯著高于對(duì)鈉、鉀等一價(jià)陽(yáng)離子的偏好。它對(duì)二價(jià)...
2025/11/4 14:22:46
9月開(kāi)學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實(shí)驗(yàn)室封口膜：技術(shù)與國(guó)際市場(chǎng)的雙重突破
在實(shí)驗(yàn)室耗材領(lǐng)域，封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來(lái)，Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實(shí)驗(yàn)室封口膜的5大突破
Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國(guó)產(chǎn)技術(shù)突破和品牌突破，是生物領(lǐng)域中國(guó)技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個(gè)重要環(huán)節(jié)，也是最容易被忽視的--芯片鍵合。其中一個(gè)重要因素是：微流控...
2023/7/27 12:44:28
驗(yàn)動(dòng)物圖.png)
熒光素鉀鹽使用說(shuō)明
D-熒光素鉀鹽（K+）設(shè)計(jì)用于體外和體內(nèi)生物發(fā)光測(cè)定。D-熒光素的質(zhì)量和純度對(duì)于獲得良好和可重復(fù)的結(jié)果至關(guān)重...
2023/7/20 11:05:11
如何選BSA（牛血清白蛋白）
如何選BSA（牛血清白蛋白）：牛血清白蛋白（BSA）有多種形式，如何選擇適合自己的牛血清白蛋白（BSA）是一...
2023/2/14 13:09:18
